Connect with us

Featured

Regen BioPharma Inc (OTCMKTS: RGBP) Major Reversal Brewing as Biotech Looks to Commercialize its Modified mRNA anti-cancer Vaccine & Accelerate Clinical Development of its NR2F6 Therapies

Published

on

Regen BioPharma Inc (OTCMKTS: RGBP) has been steadily dropping since topping out at $0.0819 in September of last year. Now it looks like its oversold and ready for a major reversal and speculators are beginning to accumulate into the selling which is starting to wane at current levels. RGBP has a massive following of shareholders, many of them international that will jump on board at any hint that the bottom has been reached; once RGBP begins to move to the upside it could be fast and furious. The Company has accomplished a lot since the last time we reported on it when they had just accomplished a number of wins including going “pink current” and becoming fully compliant, settlings the lawsuit with Chemdiv, growing the Companys valuable patent portfolio as well as granting two licensees to Oncology Pharma for which RGBP was paid $1,905,000 in cash and securities. More recently Regen began a development program to commercialize its modified mRNA anti-cancer vaccine targeting the Survivin protein. They also announced a program to accelerate the clinical development of its NR2F6 therapies. The Company intends to combine modified mRNA technology with Regen’s existing siRNA (small interfering RNA) intellectual property targeting the NR2F6 nuclear receptor which has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator.  

Microcapdaily has been reporting on RGBP since early last year. The last time we covered the Company we stated among other things: “RGBP is one of the most followed stocks in small caps with a huge investors base and it has a long history of big moves skyrocketing to 8 cents plus twice over the past 12 months. There are also plenty of buyout rumors on RGBP; according to many investors It appears there may be a possible merger acquisition looming with Precigen or another big pharma which would make sense as the CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $766 million. RGBP is in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that Precigen is in including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP or does a merger acquisition and the motive to do this are the numerous valuable Patents RGBP owns that address enormous billion-dollar markets.” 

Regen BioPharma Inc (OTCMKTS: RGBP) is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders.  

Regen owns a valuable intelectuable property portfolio including 8 issued patents and 13 published patent applications. Zander Therapeutics, Inc. (a company under common control) has been granted an exclusive license to develop and commercialize IP controlled by the Company for non-human veterinary therapeutic use. Regen has granted an exclusive license to Oncology Pharma, Inc. to develop and commercialize “Antigen specific mRNA cellular cancer vaccines” for the treatment of pancreatic cancer and KCL Therapeutics, Inc. has granted an exclusive license to Oncology Pharma, Inc. to develop and commercialize certain intellectual property for the treatment of colon cancer. 

The Company is led by CEO David Koos who has over 30 years of investment banking and venture capital experience.  He has a deep knowledge of startup businesses, public markers and SEC reporting companies.  Dr. Koos has extensive relationships with large and small financial institutions, hedge funds and entities that Regen BioPharma expects to leverage for company growth. Dr. Koos has a Ph.D. in Sociology and a Doctor of Business Administration with an emphasis in finance.  Additionally, he has authored / co-authored numerous peer reviewed journal articles. Dr. Koos worked hard to get the filings up to date and get the Company compliant which has recently been completed with RGBP now “pink current”  

https://twitter.com/TrelloThaGod/status/1509124476910374915

To Find out the inside Scoop on RGBP Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RGBP

On February 11 RGBP announced it is embarking on a development program to commercialize its modified mRNA anti-cancer vaccine targeting the Survivin protein.  In the first phase of the development program, Regen will design and have experiments carried out that will form the initial series of pre-clinical studies required as part of an FDA IND submission. The patented technology (patent issued in Aug, 2021) is a cellular vaccine that uses a modified mRNA molecule expressing peptides of Survivin which are exposed to dendritic cells.  These dendritic cells are then matured and infused into the cancer patient’s circulation where they are expected to home in on the cancer and destroy it.  There are currently several clinical trials ongoing in the U.S. and Europe using Survivin as a vaccine for multiple different cancers which further supports this approach. 

Survivin is the smallest member of the Inhibitor of apoptosis (IAP) family of proteins, involved in inhibition of apoptosis (a form of programmed cell death that occurs in multicellular organisms) and regulation of cell cycle. These functional attributes make Survivin a unique protein regulating cell proliferation and cell death. Expression of Survivin in tumors correlates with not only inhibition of apoptosis and a decreased rate of cell death, but also resistance to chemotherapy and aggressiveness of tumors. Therefore, Survivin is an important target for cancer vaccines and therapeutics. This technology has been out-licensed for use in pancreatic cancer which leaves Regen dozens of other potential indications. 

In February Oncology Pharma, Inc. announced it will jointly develop Regen’s patented ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES (“MRNA Vaccines”). In April of 2021 ONPH was granted an exclusive right and license for the development and commercialization of the MRNA Vaccines for the treatment in humans of pancreatic cancer. The current intent is that IND (“Investigational New Drug Application”) enabling studies are to be commenced and completed with Regen providing the scientific expertise, laboratory access and modified mRNA and cellular manufacturing needed to complete the studies and ONPH providing the required financing. 

On March 10 RGBP announced a program to accelerate the clinical development of its NR2F6 therapies. The Company intends to combine modified mRNA technology with Regen’s existing siRNA ( small interfering RNA)  intellectual property targeting the NR2F6 nuclear receptor which has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. mRNA is a single-stranded molecule that carries genetic code from DNA in a cell’s nucleus to ribosomes (the cell’s protein-making machinery).    

Regen has filed an Investigational New Drug Application  (IND#16928) for their drug termed tCellVax   with the U.S. FDA. tCellVax is intended to utilize siRNA to silence NR2F6 activity in human immune cells thereby activating these immune cells in such a way that they can attack cancer cells. The Company believes that adding new intellectual property utilizing modified mRNA will profoundly simplify the drug development process and thus speed development. Dyo Biotechnologies has been contracted to assist Regen with the development of the above mentioned technology. Regen is in the process of drafting a new patent application pertaining to this intellectual property. 

For more on RGBP Subscribe Right Now!

Currently trading at a $28 million market valuation RGBP has 4,580,002,832 shares outstanding and a debt load that has caused significant dilution in the past. But RGBP is an exciting story developing in small caps, at current levels the selling pressure that decimated the share price from over $0.08 to half a penny is waning and many speculators are accumulating with a belief that a major reversal is about to happen. As we said, once RGBP begins to move to the upside it could be fast and furious. RGBP is no stranger to big moves and has runner in its blood skyrocketing to $0.0819 not once but twice in the past year alone. The stock is currently trading well below established support levels at $0.01 just a year ago and has a significant gap to fill from current levels. We will be updating on RGBP when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with RGBP.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in RGBP either long or short and we have not been compensated for this article

Featured

Clean Vision Corp (OTC: CLNV): Overcoming the Plastic Waste Crisis

Published

on

Clean Vision Corporation (OTC: CLNV) has experienced several interesting developments recently, but it hasn’t noticeably influenced the market with any substantial gains. Nonetheless, we believe it’s worth providing an update on the company given it’s been a few months since our last mention. In today’s discussion, we’ll explore a variety of updates and their significance, with aim of providing insight on what to expect for 2024.

Background:

Clean Vision is led by Dan Bates, and their goal is to tackle the global plastic waste crisis head-on. Their wholly owned subsidiary, Clean Seas, has developed the Plastic Conversion Network (PCN), a groundbreaking technology aimed at diverting millions of tons of waste plastic from landfills, incineration, and oceans. The PCN converts this plastic feedstock into clean fuels and green hydrogen, significantly reducing reliance on fossil fuels and lowering the carbon footprint.

For a brief 2 minute overview on the company, feel free to reference the video CLNV’s subsidiary put together on YouTube. Here’s the link.

Clean Seas utilizes proven pyrolysis technology to produce environmentally friendly products, which are sold to multinational petrochemical companies, driving the circular plastic economy. Operational PCN facilities are already in place in Morocco and India, with additional conversion facilities in development across West Virginia, Arizona, and Southeast Asia. Long-term feedstock supply agreements exceeding one million tons of waste plastic annually have been secured at no cost.

Their recently trademarked brand, AquaH®, is produced in their PCN. According to the release, it offers a differentiated green hydrogen product from carbon-neutral sources. Currently, hydrogen is predominantly produced through methods that involve fossil fuels, which of course contributes to global carbon emissions. Furthermore according to Deloitte’s 2023 global green hydrogen outlook, this could be a $1.4T annual market by 2050.

$65 Million Plastic Conversion Facility:

CLNV is making big moves in West Virginia and according to the release on October 24th, 2023, they’ve brought in some serious players—CDI Engineering Solutions and ERM—to help out with their Clean-Seas West Virginia project.

CDI has over 70 years of experience integrating engineering, design, project support, procurement and construction management services to the energy, chemicals and electrical infrastructure markets.

ERM is the world’s largest advisory firm focused solely on sustainability, offering environmental, health, safety, risk and social expertise for more than 50 years with more than 8,500 dedicated professionals operating across 40 countries.

The plan is to kick things off in 2024, turning 100 tons of plastic every day into recycled plastics and clean fuels. It’s a hefty project with a $65 million investment, creating over 200 jobs initially. And they’re not stopping there—they want to scale up to 500 tons of plastic per day over time.

West Virginia Governor Jim Justice is also on board, throwing over $12 million in state incentives to support the project.

Governor Jim Justice made a reference to Clean Seas in his state of the union address. If you want to catch the mention, go to 34:15 in the video. The three minutes leading up to it are also worth reviewing.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Launches Global Operations:

CLNV made another significant advancement, planning to launch waste plastic conversion facilities in the European Union, Eastern Europe, and Southeast Asia. This will be accomplished through their new subsidiary, Clean-Seas Partners UK Limited (CS-UK), who of course shares the same vision of creating sustainable solutions to the global plastic pollution crisis.

Under the leadership of Managing Director Shaun Wootton, CS-UK will play a crucial role in strategic project development and investment facilitation, leveraging established relationships in the Middle East, Southeast Asia, and Europe.

To fortify effective governance and strategic direction, CS-UK is assembling a distinguished board with internationally recognized figures in banking, sustainability, and energy. This approach aims to have a diverse and experienced board guiding CS-UK in realizing its vision of promoting sustainability and environmental stewardship across diverse regions.

$340 Million Bond Offering:

CLNV even announced they partnered with a global advisory firm, Grant Thornton, to issue up to $340 million in Green Bonds. This is the world’s sixth-largest network of independent accounting and consulting firms, employing 62,000 people in more than 130 countries and had revenues of $6.6 billion in 2021. These bonds will fund the expansion of Clean Vision’s Plastic Conversion Network (PCN) under the “Clean-Seas” initiative worldwide, aimed at combatting plastic pollution on a global scale.

With the Green Bond’s net proceeds, CLNV plans to deploy at least six plastic waste conversion lines globally, with strategic locations in West Virginia, Arizona, Southeast Asia, and expansion in Morocco. The Green Bond is also expected to attract environmentally conscious investors, setting a new standard for corporate responsibility.

$15M Government Loan:

Lastly, under the capable management of Huntington Bank, CLNV has recently secured a $15 million government loan. What sets this apart is that the loan is FORGIVABLE.

A forgivable loan is a type of loan where the borrower is not required to repay the borrowed amount under certain conditions. Typically, these conditions are related to the borrower meeting specific criteria, such as using the funds for approved purposes, maintaining certain employment levels, or achieving predetermined goals. If the borrower fulfills these conditions, the loan is forgiven, and they are not obligated to repay the borrowed amount. Forgivable loans are often used as an incentive or support for specific activities, such as job creation, small business development, or other initiatives that contribute to economic growth or community welfare.

Not to mention it won’t result in any dilution for shareholders. This is an unexpected and uncommon accomplishment for an OTC company. Securing a government loan of this size without any dilution is truly impressive.

Conclusion:

CLNV has made impressive strides tackling the global plastic waste crisis, especially given their valuation of merely $22.65 million. The team has swiftly achieved key objectives, including a $65 million plastic conversion facility in West Virginia, global expansion through Clean-Seas Partners UK Limited, a $340 million Green Bond Offering, and a remarkable $15 million forgivable government loan. The vast $1.4 trillion market they’re tapping into offers an interesting opportunity with current indicators looking positive. Nevertheless, it’s crucial to acknowledge that there is still significant work ahead, and the team needs to maintain consistent execution to turn this potential into a reality.

We will update you on CLNV when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by pasja1000 from Pixabay

Continue Reading

Featured

Meta Materials (NASDAQ: MMAT): More Due Diligence and Exploring Latest Developments

Published

on

Meta Materials (NASDAQ: MMAT) witnessed a significant uptick in trading activity on January 16th, 2024, resulting in a notable 20% increase in its stock value by market close. Intrigued by this surge, we explored various sources, including press releases, SEC filings, and social media, to identify the catalyst behind this sudden gain.

Unexpectedly our research revealed no recent material releases. Instead, the surge seems tied to an announcement from a few days ago that didn’t grab much attention at first. As time passed, it started generating more buzz but there’s still a lot more to dig into and a number of ideas to consider for today’s rally.

If you haven’t caught up on our previous analyses of MMAT, you can find the overview here. In this report, we aim to explore the cause-and-effect dynamics of recent events, offering insights that might illuminate expectations for Meta Materials in the near future.

Background:

If you’re new to MMAT or haven’t been a long-time follower, let’s kick things off with a quick intro to the company.

Meta Materials stands at the forefront of advanced materials and nanotechnology. Their focus is on pioneering novel products and technologies utilizing sustainable and innovative scientific approaches. The interesting part is their advanced materials have the transformative power to enhance a variety of common products, infusing them with heightened intelligence and sustainability.

Leveraging its technology platforms, they’re capable of empowering global brands in creating cutting-edge products that elevate overall performance.

Their technology has application across multiple industries including aerospace and defense, consumer electronics, 5G communications, batteries, authentication, automotive, and clean energy. Their agreement with Panasonic is certainly a great start to empowering their growth in one of many verticals. Overall the TAM is ~$32B and with current growth rates, it’ll increase to a whopping ~$61B by 2026.

MMAT’s goal is to shape a smarter and more sustainable world. If you look through their presentation, you can continue to evaluate the many ways their technology transforms everyday lives. We highly suggest you take a look.

Additional Resources:

  1. @LauraLoomer’s video on MMAT
  2. @metaheadj’s post on X, displaying Rob Stone‘s response update for an investor

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What Happened:

So, MMAT issued a press release on January  11th, 2024, announcing a proposed settlement with the Securities and Exchange Commission (SEC) concerning an investigation related to the Torchlight Energy Resources, Inc. and Metamaterial Inc. merger.

According to the release, The company has extended a settlement offer (Proposed SEC Settlement) to the SEC’s Division of Enforcement. This proposed settlement aims to address concerns regarding antifraud, reporting, books and records, and internal accounting control provisions of securities laws. It is important to note that the Proposed SEC Settlement is contingent on approval by the SEC Commissioners, and the company cannot predict the approval timeline.

If accepted, the Proposed SEC Settlement would involve the SEC entering a cease-and-desist order and the company paying a civil money penalty of $1 million over a one-year period in four installments. Notably, the company would neither admit nor deny the findings outlined in the Order.

The company’s board of directors and management team view the Proposed SEC Settlement as beneficial for shareholders. If approved, it is expected to remove uncertainty surrounding the investigation, enabling the company to focus on advancing its business objectives.

So What:

If you’ve just read through the announcement and are confused, you’re not alone. It appears that many investors may have mis-read the press release, thinking that the SEC was being punished and MMAT was reaching a settlement agreement, but it appears to be the other way around.

In the event of approval, the company is obligated to pay a civil money penalty of $1 million. This penalty would be paid in four installments over the course of one year, following an agreed-upon payment plan. However, the PR also notes that the company cannot predict with certainty whether or when the Proposed SEC Settlement will even be approved by the SEC Commissioners.

According to another user on X, @AShortSqueeze, MMAT’s initial analysis has potentially revealed the motherload of counterfeit shares.

But if you scroll through the comments, you’ll see other users pointing out that this information is actually old news. This is just one of many widely circulated posts that might have been misunderstood.

Significant Coverage:

Another theory suggests that a notable influencer in the financial space, @MoonMarket_, has set their sights on the company and is conducting additional due diligence. With a substantial following of almost 75K users, the influencer’s involvement could have contributed to a significant fluctuation in today’s trading session. It’s important to recognize that X is packed with plenty of financial influencers, and blindly following their moves can be risky. Many are involved in day trades, momentum trading, or at least contemplating such strategies.

Conclusion:

The buzz around MMAT today seems fuelled by a mix of misrepresented themes and recycled news, creating the illusion of fresh, imminent developments.

As per usual, the magnitude of MMAT’s technology and potential integrations across various verticals continues to create a roar of excitement. On another front, we’re also continuing to see speculation about a short squeeze due to substantial amounts of counterfeit shares.

For now, patience is key and we suggest closely monitoring developments. MMAT especially tends to be quite volatile.

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by StartupStockPhotos from Pixabay

Continue Reading

Featured

Integrated Cannabis Solutions’ (OTC: IGPK) 633% Surge: Exploring Catalysts, Company Overview, and Growth Potential in 2024

Published

on

Integrated Cannabis Solutions (OTC: IGPK) has undergone a remarkable uptrend, surging an impressive 633% since December 11th, 2023, with 166% of that surge taking place across yesterday’s trading session and today, January 11th, 2023. Both days have been marked by unprecedented volume – Yahoo Finance reported an almost 30x increase, with 115,867,027 shares traded by close yesterday. We’re already seeing 90,092,317 shares traded this morning and it’s just barely noon. Today we’ll explore the catalysts behind the surge, offer a comprehensive overview of the company, and evaluate IGPK’s potential for sustained growth throughout 2024.

Background:

Let’s get straight to it. IGPK is the result of a recent reverse merger with Integrated Cannabis Solutions and JFH Digital E-Commerce Corp. The first thing you’ll notice is finding the website isn’t a walk in the park, we’re fairly certain there isn’t one yet, at least one that will help in any way related to more investment information. Your best bet for more any information is to check out IGPK’s OTC Market page for details, but even the company description on there is not accurate. We’ve mainly found the following information through filings, IGPK’s Twitter, and other online users.

Keep in mind this breakdown might not be flawless given we’re piecing it together mostly from what folks on X are saying. But we’ll try our absolute best to lay it all out for you.

IGPK appears to have been a shell for little while until JFH stepped in. A user on X, @stockplayer30, broke it down fairly simply, stating that the shell’s slate was wiped clean, cancelling all notes payable and any debt. Whether it’s a promissory note, convertible note, or convertible debenture, the main point is they ditched all debt. JFH has an opportunity to start fresh, and it certainly makes this deal a lot more interesting.

Just a heads up, it’s a Chinese merger. If the idea of a Chinese leadership team makes you a bit wary, you might want to pause here. However if you were in the trading game during the summer of ’23, you probably remember those crazy spikes in some Chinese Nasdaq deals. And get this – no big press releases or SEC filings to explain those sudden jumps either.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Company Description:

Onto what the company actually does. According to @SuperRobotOTC on X, this is a digital e-commerce company based in China, here’s a link to their e-commerce website. This user also put together a great overview of the company on YouTube, if you’d like to watch something informative in video format, click here.

Another user, @igal_n, found a blurb on the company that states, “Junfenghuang (JFH) is a digital asset. It is a token issued by Uplus Future Company with the help of blockchain technology. It has no direct relationship with the original equity”.

The Potential:

What makes this story extremely interesting is the sheer magnitude of how large JFH is, the intrinsic value does not appear to be valued accurately in the market, given it’s only freshly merged into IGPK’s tiny shell company on the OTC.

Their Gross Merchandise Value (GMV) is heading north of 50 billion yuan, and post-merger profits from service outlets are looking at a hefty 10 billion yuan – yes, billion with a B.

Steering the ship is a leadership team featuring President Wang Dejun, Treasurer Xie Weiji, and Director Yang Lanfang. With a whopping 750 subsidiaries, 250,000 merchants, and 30 million registered users. We’ve also heard from other sources that the registered users could be nearly double that, coming in at 50 million registered users.

These numbers are substantial for a company with a $7 million market cap. Looking ahead, it won’t be shocking if IGPK sets its sights on moving up to a bigger exchange like NASDAQ. It’s no secret they’re already in the big leagues – or it at least appears so. If that were the case, they’d of course have enhanced credibility, more visibility, and increased access to capital with institutional funding.

The App:

Now, you might be wondering, “Sounds cool, but it’s a Chinese merger with a whole setup on the other side of the planet. Can we trust this info?” @SuperRobotOTC has also gone the extra mile by downloading the app, and gave us the lowdown in video format. On top of the SEC filings, this is an added layer of trust & credibility we can attribute to this new venture. Here’s the link to the video.

Conclusion:

Fortunately it appears IGPK is still for the most part flying under the radar. There’s not even a proper website or accurate update on IGPK’s OTC Market overview to tell us what the company even entails. But here’s the silver lining – that might mean you’re still early. The intrinsic value of IGPK appears strongly disproportionate to its current value in the market.

Our advice? Keep a close eye on IGPK’s journey as it takes on this exciting phase of growth and exploration. It’s likely this story will catch wind quickly and it could be a great time to take advantage. As @SuperRobotOTC eluded to in his video, this could be the OTC’s largest merger, with a potential $70B valuation.

We will update you on IGPK when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by geralt from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.